Backed by some of the biggest names in biotech, Norbert Bischofberger gets his megaround for platform tech out of MIT
A little over a year ago when I reported on Norbert Bischofberger’s jump from the CSO job at giant Gilead to a tiny upstart called Kronos, I noted that with his connections in biotech finance, that $18 million launch round he was starting off with could just as easily have been $100 million or more.
With his first anniversary now behind him, Bischofberger has that mega-round in the bank.
Basic subscription required
Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.